Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature.
J Gastrointest Oncol
; 14(1): 352-365, 2023 Feb 28.
Article
in En
| MEDLINE
| ID: mdl-36915455
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Clinical_trials
/
Prognostic_studies
Language:
En
Journal:
J Gastrointest Oncol
Year:
2023
Document type:
Article
Affiliation country:
Alemania
Country of publication:
China